Publication date: Sep 18, 2025
People with lower blood levels of IgA(S) antibodies, which protect the nose and throat, were also at higher risk. Notably, the group that started with the highest antibody levels but experienced a faster decline were infected earlier. One-time blood tests for IgG antibodies, the antibody type we used for classification, couldn’t detect this risk. Previous research points to factors such as age, genetic variation, vaccine-specific characteristics, and environmental influences, including sleep habits, stress levels, and medications being taken at the same time. “In spite of their impressive initial immune response, they caught COVID-19 sooner than other groups, while durable responders maintained protection for longer periods. Both show strong antibody responses initially, but six months later one stays healthy while the other contracts the virus. “This is the first time we’ve been able to clearly group how people respond to COVID-19 vaccines. “
| Concepts | Keywords |
|---|---|
| Faster | Antibodies |
| Japan | Antibody |
| Mathematical | Blood |
| Months | Breakthrough |
| Vaccinations | Covid |
| Group | |
| Igas | |
| Immune | |
| Infection | |
| Rapid | |
| Responders | |
| Risk | |
| Vaccination | |
| Vaccine | |
| Vulnerable |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | IDO | immune response |
| disease | IDO | blood |
| disease | MESH | infection |
| disease | MESH | breakthrough infections |
| drug | DRUGBANK | Tropicamide |